

VIEWPOINTS


The right to deworming: The case for girls and women of reproductive age

Theresa W. Gyorkos¹*, Antonio Montresor², Vicente Belizario³, Beverley-Ann Biggs⁴, Mark Bradley⁵, Simon J. Brooker⁶, Martin Casapia⁷, Philip Cooper⁸, Sila Deb⁹, Nicolas L. Gilbert¹⁰, Rubina Imtiaz¹¹, Virak Khieu¹², Stefanie Knopp¹³, Ornella Lincetto¹⁴, Layla S. Mofid¹⁰, Denise Mupfasoni², Cori Vail¹⁵, Jozef Vercruyse¹⁶

1 World Health Organization Collaborating Centre for Research and Training in Parasite Epidemiology and Control, Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada, **2** Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland, **3** Department of Parasitology, College of Public Health, University of the Philippines-Manila, Philippines, **4** Department of Medicine, University of Melbourne, Parkville, Victoria, Australia, **5** GlaxoSmithKline, Twickenham, United Kingdom, **6** Neglected Tropical Diseases-Global Health, Bill and Melinda Gates Foundation, Seattle, Washington, United States of America, **7** Ciencias Médicas y de la Salud, Universidad Nacional de la Amazonia Peruana and Asociación Civil Selva Amazónica, Iquitos, Peru, **8** Department of Epidemiology of Infectious Diseases, St. George's, University of London, London, United Kingdom, **9** Child Health, Ministry of Health and Family Welfare, New Delhi, India, **10** World Health Organization Collaborating Centre for Research and Training in Parasite Epidemiology and Control, Department of Epidemiology, Biostatistics and Occupational Health, Montreal, Quebec, Canada, **11** Children Without Worms, Atlanta, Georgia, United States of America, **12** National Helminth Control Programme, National Centre for Parasitology, Entomology and Malaria Control, Ministry of Health, Phnom Penh, Cambodia, **13** Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institution and University of Basel, Basel, Switzerland, **14** Family, Women's and Children's Health, Maternal, Newborn, Child and Adolescent Health, Policy, Planning and Programmes, World Health Organization, Geneva, Switzerland, **15** STH Global Public Health, Johnson and Johnson, Raritan, New Jersey, United States of America, **16** Department of Virology, Parasitology, and Immunology, Ghent University, Merelbeke, Belgium

* These authors contributed equally to this work.

* theresa.gyorkos@mcgill.ca



OPEN ACCESS

Citation: Gyorkos TW, Montresor A, Belizario V, Biggs B-A, Bradley M, Brooker SJ, et al. (2018) The right to deworming: The case for girls and women of reproductive age. *PLoS Negl Trop Dis* 12(11): e0006740. <https://doi.org/10.1371/journal.pntd.0006740>

Editor: Jennifer F. Friedman, Brown University, UNITED STATES

Published: November 21, 2018

Copyright: © 2018 Gyorkos et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Funding for the meeting of the Advisory Group on deworming in girls and women of reproductive age was provided by the Rockefeller Foundation, the Institute of International Education (PS00248847), and the World Health Organization using grant funds from the Bill & Melinda Gates Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: 1. MB is the Director of Scientific Support for albendazole donations for GlaxoSmithKline. 2. CV is the Director, GPH; Global

Girls and women of reproductive age (WRA) bear a large burden of disease from soil-transmitted helminth (STH) infections worldwide. This burden is primarily attributable to the anemia caused by hookworm and *Trichuris trichiura* infections [1,2]. Together with preschool children (pre-SAC) and school-age children (SAC), WRA are one of the three risk groups most vulnerable to STH morbidity [3,4,5,6], yet the benefits and opportunities for addressing STH among this group have, until recently, been under-appreciated.

Mupfasoni and colleagues estimate that over 688,000,000 WRA living in STH-endemic countries were in need of deworming treatment in 2015 [5], and Montresor and colleagues have further estimated that more than 600,000 disability-adjusted life years (DALYs) are lost by WRA due to STH, annually [7]. Although coverage rates of deworming in the two child risk groups have been steadily increasing (from less than 10% in 2003 to more than 60% in 2016 [8]) through school or child health campaign platforms, coverage in WRA has not improved. Data on treatment coverage for WRA are not routinely collected by national programs, but it is likely that, as countries successfully transition out of lymphatic filariasis treatment programs (in which albendazole is included in the treatment regimen), coverage rates of deworming in WRA may decline. Moreover, although 2002 World Health Organization (WHO) guidance [9] recommended pregnant women should be treated, uptake of treatment during antenatal care has been low, due (in part) to a perceived fear of side effects, especially teratogenicity, among women and health personnel. Operational research is currently underway to identify an efficient approach to ruling out first-trimester pregnancy to respond to these concerns [10].

Program Leader STH at Johnson & Johnson. 3. RI is the Director of Children Without Worms, which was jointly founded by Johnson & Johnson and The Task Force for Global Health.

In order to expand treatment among WRA, new community-based strategies are required, with strategies tailored to reaching each of the different subgroups of WRA (i.e., adolescent girls, pregnant women, lactating women, and nonpregnant nonlactating women) [11,12]. For example, deworming can be added to iron supplementation programs targeting pregnant women, and it can be offered to lactating women at well-baby clinics.

Several government-supported platforms already exist in many countries to reach adolescent girls (e.g., schools), pregnant women (e.g., antenatal care clinics), and lactating women (e.g., postpartum and well-baby clinics). In addition, women can be reached by piggybacking onto other highly successful campaigns like Child Health Days and new efforts to increase universal health care coverage [13,14]. There are also many untapped opportunities to reach the majority of at-risk WRA and innovative approaches (e.g., use of social technologies, among others) will be needed to ensure that coverage is optimal. With these opportunities also come challenges that will need to be overcome. First, there is no drug donation program for WRA, with current donation programs for SAC only. Second, special considerations need to be made

Every girl and every woman of reproductive age who is infected with soil-transmitted helminths has the right to be treated.

Because... intestinal worm infections of moderate and heavy intensity, especially hookworm and whipworm infections, cause substantial morbidity in girls and women of reproductive age.

Because... treatment is safe and effective at reducing morbidity, including during pregnancy (after the first trimester) and during breastfeeding.

Because... girls and women of reproductive age living in areas endemic for soil-transmitted helminth infections who present to a health service should be treated on a case-by-case basis.

For logistic and cost-effective reasons, where the prevalence of soil-transmitted helminth infection in a community equals or exceeds 20%, targeted preventive chemotherapy of all girls and women of reproductive age in the community is recommended. Preventive chemotherapy targeted to this group at risk can be delivered through many different venues including schools, households, health facilities such as antenatal care clinics, and other appropriate venues.

Fig 1. The Bellagio Declaration.

<https://doi.org/10.1371/journal.pntd.0006740.g001>

for women who are pregnant, as deworming is contraindicated in the first trimester. Third, appropriate messaging is required to educate women and health personnel of the safety and benefits of deworming in order to help allay fears of perceived side effects. Finally, there are a number of outstanding basic and operational research issues that merit further investigation, including monitoring and evaluating the impact of deworming programs targeting WRA on maternal and infant outcomes and evaluating the cost-effectiveness of different platforms for reaching WRA, among others.

Clear policy and guidance are also essential to support country efforts to expand routine deworming of WRA, and two recent WHO publications have provided the necessary policy framework. The first is the new evidence-informed guideline on preventive chemotherapy which documents deworming recommendations for all three high-risk groups (SAC, pre-SAC, and WRA [including adolescent girls]) [15]. It reaffirms deworming in all at-risk WRA subgroups, including pregnant women, after the first trimester. The second, a report of an international expert advisory group meeting, is the 2018 update to the 1994 Report of the WHO Informal Consultation on Hookworm Infection and Anemia in Girls and Women [16, 17]. This report, focusing specifically on WRA, summarizes the group's deliberations, outlining a set of recommendations and research priorities, and informing the meeting's unanimously adopted Bellagio Declaration (Fig 1).

This declaration represents a seminal landmark for the promotion of the rights and livelihoods of WRA living in STH-endemic areas of the world. All stakeholders in women's health should take immediate action in their respective domains to ensure that WRA are now included in their STH policies, programs, and clinical and operational research priorities. Such collective action will ensure that every girl and woman of reproductive age at-risk of STH can benefit from effective treatment.

References

1. Foy H, Nelson GS. Helminths in the etiology of anemia in the tropics, with special reference to hookworms and schistosomes. *Exp Parasitol*. 1963; 14:240–262. PMID: [14072770](#)
2. Gyorkos TW, Gilbert NL, Larocque R, Casapia M. *Trichuris* and hookworm infection associated with anaemia during pregnancy. *Trop Med Inter Health*. 2011; 16(4):531–537.
3. Brooker S, Hotez PJ, Bundy DAP. Hookworm-related anaemia among pregnant women: a systematic review. *PLoS Negl Trop Dis*. 2008; 2(9):e291. <https://doi.org/10.1371/journal.pntd.0000291> PMID: [18820740](#)
4. Hotez P, Whitham M. Helminth infections. A new global women's health agenda. *Obstetrics & Gynecology*. 2014; 123(1):155–160.
5. Mupfasoni D, Mikhailov A, Mbabazi P, King J, Gyorkos TW, Montresor A. Estimation of the number of women of reproductive age in need of preventive chemotherapy for soil-transmitted helminth (STH) infections. *PLoS Negl Trop Dis*. 2018; 12(2): e0006269. <https://doi.org/10.1371/journal.pntd.0006269> PMID: [29432423](#)
6. Smith JL, Brooker S. Impact of hookworm infection and deworming on anaemia in non-pregnant populations: a systematic review. *Trop Med Inter Health*. 2010;15(7):776–795.
7. Montresor A, Trouleau W, Mupfasoni D, Bangert M, Joseph SA, Mikhailov A. et al. Fitzpatrick C. Preventive chemotherapy for the control of soil transmitted helminthiasis averted more than 500 thousand DALYs in 2015. *Trans R Soc Trop Med Hyg*. 2017; 121(10):457–463.
8. World Health Organization. Schistosomiasis and soil-transmitted helminthiasis: number of people treated in 2016. *Wkly Epidemiol Rec*. 2017; 92(49):749–760. PMID: [29218962](#)
9. World Health Organization. Prevention and control of schistosomiasis and soil-transmitted helminthiasis. Report of a WHO Expert Committee. Geneva: World Health Organization; 2002. WHO Technical Report Series 912.
10. COR-NTD. Report 1D. Access for women of reproductive age to deworming.pdf. Available from: <http://www.ntdsupport.org/resources/outputs-2017-cor-ntd-meeting>. [cited 2018 July 17].
11. Ahuja A, Baird S, Hicks JH, Kremer M, Miguel E, Powers S. When should governments subsidize health? The case of mass deworming. *World Bank Econ Rev*. 2015; 1(Suppl1):S9–S24.

12. Mofid LS, Gyorkos TW. The case for maternal postpartum deworming. *PLoS Negl Trop Dis*. 2017; 11(1):e0005203. <https://doi.org/10.1371/journal.pntd.0005203> PMID: 28056019
13. Palmer AC, Diaz T, Noordam AC, Dalmiya N. Evolution of the Child Health Day strategy for the integrated delivery of child health and nutrition services. *Food Nutr Bull*. 2013; 34(4):412–419. <https://doi.org/10.1177/156482651303400406> PMID: 24605691
14. UHC2030. Available from: <https://www.uhc2030.org/>. [cited 2018 July 17].
15. World Health Organization. Guideline: Preventive chemotherapy to control soil-transmitted helminth infections in at-risk population groups. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
16. World Health Organization. Report of the WHO Consultation on hookworm infection and anaemia in girls and women. Geneva: World Health Organization; 1996. WHO/CTD/SIP/96.1.
17. World Health Organization. Reaching girls and women of reproductive age with deworming: Report of the WHO Advisory Group on deworming in girls and women of reproductive age. Geneva: World Health Organization; 2018. WHO/CDS/NTD/PCT/2018.01